GlassScriptPhysician profile
Andrea Coffey
NPI 1891179503
$7,659.86
in general payments reported to CMS, 2019-2025
31 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $1,161 · 2023: $2,092 · 2024: $1,672 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,442 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,442.38 |
| Education | $187.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,991.23 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,132.26 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $867.91 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $425.66 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Ferring Pharmaceuticals INC. | $321.40 | 2021-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $289.91 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $256.69 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $244.70 | 2021-2023 | |
| Ardelyx, INC. | $238.76 | 2023-2025 | Ibsrela |
| Celgene Corporation | $179.97 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $162.05 | 2023 | Epclusa |
| Phathom Pharmaceuticals, INC. | $145.59 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $131.74 | 2021-2025 | Ocaliva |
| Celltrion USA INC. | $129.94 | 2024-2025 | Vegzelma |
| Madrigal Pharmaceuticals | $128.92 | 2025 | Rezdiffra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $127.94 | 2022-2025 | Dupixent |
| Intra-Sana Laboratories | $100.00 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Pfizer INC. | $93.60 | 2021-2025 | |
| Lilly USA, LLC | $92.80 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $84.08 | 2021-2023 | Injectafer |
| Genzyme Corporation | $77.96 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $77.10 | 2023 | |
| Redhill Biopharma INC. | $63.11 | 2021-2022 | |
| Evoke Pharma, INC. | $62.95 | 2022-2024 | |
| Braintree Laboratories, INC. | $55.74 | 2022-2025 | Suflave |
| Organon LLC | $53.44 | 2024-2025 | Renflexis, Hadlima |
| Enterra Medical, INC. | $48.03 | 2023 | |
| Ironwood Pharmaceuticals, INC | $32.24 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.53 | 2024 | |
| Amgen INC. | $14.64 | 2023 | Avsola, Amjevita |
| Amag Pharmaceuticals, INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.